S-1: Aspira Women's Health Seeks $13.8 Million in Public Offering Amidst Nasdaq Delisting Concerns

Aspira Women's Health is offering up to 16 million shares of common stock and pre-funded warrants to raise capital, while also facing potential delisting from the Nasdaq Capital Market.

Summary

• Aspira Women's Health is conducting a public offering of up to 16 million shares of common stock at an assumed price of $0.75 per share, along with pre-funded warrants for certain investors.
• The company aims to raise approximately $10.6 million in net proceeds, or $12.3 million if underwriters fully exercise their over-allotment option.
• The funds are intended for working capital and general corporate purposes, with potential for acquisitions or investments in complementary businesses.
• The offering includes pre-funded warrants exercisable at $0.001 per share, designed for investors who would otherwise exceed ownership limits.
• Aspira is facing potential delisting from the Nasdaq Capital Market due to not meeting the minimum market value of listed securities requirement.
• The company has requested an appeal to stay the delisting, but there is no guarantee of success.
• Additionally, Aspira is not in compliance with the minimum bid price requirement of $1.00 per share and has until April 15, 2025, to regain compliance.
• The company is a smaller reporting company and has elected to rely on exemptions from certain disclosure requirements.
• Aspira is focused on developing AI-enabled diagnostic tests for gynecologic diseases, including ovarian cancer and endometriosis.
• The company has a pipeline of products including OVAinform and ENDOinform, and is expanding its commercial reach through its Aspira Synergy platform.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in product development and market expansion, the company is facing significant challenges with Nasdaq listing compliance and financial stability. The need for a capital raise and the potential for delisting create a negative sentiment.

Positives

• Aspira is actively developing new AI-enabled diagnostic tests for gynecologic diseases.
• The company has a strong focus on innovation and has a history of successful product launches.
• Aspira has an extensive biospecimen repository, which supports the development of new algorithms and diagnostic tests.
• The company is expanding its commercial reach through its direct sales force, channel partners, and Aspira Synergy platform.
• Aspira has secured funding from ARPA-H to develop a new endometriosis diagnostic test.
• The company has expanded its distribution agreement with BioReference to include OvaWatch.
• The average OvaSuite volume per field sales representative increased by nearly 21% in the nine months ended September 30, 2024, compared to the same period in 2023.

Negatives

• Aspira is facing potential delisting from the Nasdaq Capital Market due to not meeting the minimum market value of listed securities requirement.
• The company is also not in compliance with the minimum bid price requirement of $1.00 per share.
• The company has a history of losses and may continue to incur losses in the future.
• The company's stock price has been highly volatile.
• The company's management has broad discretion as to the use of the net proceeds from the offering.
• The company's stockholders may experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase in the offering.

Risks

• The company's stock price has been and may continue to be highly volatile.
• There is a risk that the company may not use the proceeds from the offering effectively.
• Investors may experience immediate and substantial dilution in the net tangible book value per share.
• The company may need to raise additional capital in the future, which could dilute existing stockholders.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• The company may be delisted from the Nasdaq Capital Market if it fails to comply with continued listing requirements.
• There is no established public trading market for the pre-funded warrants being offered.
• The company operates in a competitive and rapidly changing environment.
• The company's ability to continue as a going concern is dependent on its ability to raise capital and generate revenue.

Future Outlook

Aspira plans to broaden its commercial focus to include a range of gynecological diseases, expand its product offerings, and increase market penetration through its direct sales force, channel partners, and Aspira Synergy platform. The company also intends to continue to raise public awareness regarding the higher sensitivity and negative predictive value for ovarian malignancy of Ova 1 as compared to cancer antigen 125 (CA-125) on its own for women with adnexal masses planned for surgery, as well as the performance of our machine learning algorithms in detecting ovarian cancer risk in different racial and ethnic populations.

Management Comments

• The company continues to focus on three key initiatives: growth, innovation, and operational excellence.
• The company expects its extensive experience with gynecologists and healthcare providers, along with the historical adoption of its OvaSuite tests, to drive growth as it introduces new products.
• The company believes its ability to successfully develop novel AI-enabled assays is superior to others based on its knowledge and extensive experience in designing and successfully launching FDA-cleared and laboratory developed blood tests to aid in the diagnosis of ovarian cancer.

Industry Context

The announcement comes as the diagnostic technology industry is experiencing significant price and volume fluctuations. Aspira is positioning itself to capitalize on the growing demand for non-invasive diagnostic tests for gynecologic diseases, particularly ovarian cancer and endometriosis. The company's focus on AI and machine learning aligns with broader industry trends towards precision medicine and personalized treatment plans.

Comparison to Industry Standards

• The document mentions that Ova1 achieved parity with CA-125 as a Level B clinical recommendation for the management of adnexal masses, which is a significant achievement in the context of industry standards.
• The company's OvaWatch test is the only commercially available blood test for assessment of the risk of ovarian cancer in women diagnosed with an adnexal mass considered indeterminate or benign by a physician's preliminary clinical assessment, which gives it a competitive advantage.
• The company's focus on multi-marker tests combining serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer and endometriosis is in line with the industry's move towards more comprehensive and accurate diagnostic tools.
• The company's collaboration with world-class research and academic institutions, such as Harvard's Dana-Farber Cancer Institute and Brigham and Women's Hospital, is a positive sign of its commitment to scientific rigor and innovation, which is comparable to other leading companies in the diagnostic space.

Management Changes

Related Party Transactions

• Certain stockholders, including directors and officers, have participated in previous offerings.
• The company has a Stockholders Agreement with certain investors that grants them rights to participate in future equity offerings and prohibits the company from taking certain actions without their consent.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to stock price volatility and potential delisting.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and patients may benefit from the development of new diagnostic tests, but may also be affected by any disruptions to the company's operations.
• Suppliers and creditors may be impacted by the company's financial situation and ability to meet its obligations.

Next Steps

• The company will continue to pursue its appeal to stay the delisting from Nasdaq.
• Aspira will work to regain compliance with the minimum bid price requirement by April 15, 2025.
• The company will continue to develop and commercialize its diagnostic tests, including OVAinform and ENDOinform.
• Aspira will continue to expand its commercial reach through its direct sales force, channel partners, and Aspira Synergy platform.
• The company will work with ARPA-H to develop and launch its endometriosis diagnostic test.
• Aspira will continue to seek payer coverage and reimbursement for its products.

Key Dates

Keywords

Ovarian Cancer, Endometriosis, Diagnostic Tests, AI, Machine Learning, Biomarkers, Nasdaq, Public Offering, Pre-funded Warrants, Aspira Synergy, OvaWatch, OVAinform, ENDOinform